Aporon (apomorphine oromucosal spray) / Orion Corp, Criceto IKM - LARVOL DELTA

Orion and Criceto Announce a License Agreement for APORON, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease (GlobeNewswire) - "Orion Corporation...today announced the signing of an exclusive license agreement for the development and commercialization of APORON, a novel apomorphine oromucosal spray for the treatment of OFF episodes in patients with Parkinson’s disease. APORON is currently in Phase 3 development by Criceto. Under the terms of the agreement, Orion will be granted an exclusive license to Criceto’s proprietary oromucosal apomorphine spray, in all global markets excluding the United States and Canada."

Licensing / partnership • Parkinson's Disease